Clinical Trial Update: Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the efficacy and safety of MP-424 in combination with peginterferon alfa-2a and ribavirin in treatment-naïve or relapsed chronic hepat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MP-424
• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Chronic Hepatitis C (CHC) | Phase 3 | Status: COMPLETED | Results posted: 2016-10-03